Literature DB >> 17204604

Activin a efficiently specifies definitive endoderm from human embryonic stem cells only when phosphatidylinositol 3-kinase signaling is suppressed.

Amanda B McLean1, Kevin A D'Amour, Karen L Jones, Malini Krishnamoorthy, Michael J Kulik, David M Reynolds, Alan M Sheppard, Huiqing Liu, Ying Xu, Emmanuel E Baetge, Stephen Dalton.   

Abstract

Human ESCs (hESCs) respond to signals that determine their pluripotency, proliferation, survival, and differentiation status. In this report, we demonstrate that phosphatidylinositol 3-kinase (PI3K) antagonizes the ability of hESCs to differentiate in response to transforming growth factor beta family members such as Activin A and Nodal. Inhibition of PI3K signaling efficiently promotes differentiation of hESCs into mesendoderm and then definitive endoderm (DE) by allowing them to be specified by Activin/Nodal signals present in hESC cultures. Under conditions where hESCs are grown in mouse embryo fibroblast-conditioned medium under feeder-free conditions, approximately 70%-80% are converted into DE following 5 days of treatment with inhibitors of the PI3K pathway, such as LY 294002 and AKT1-II. Microarray and quantitative polymerase chain reaction-based gene expression profiling demonstrates that definitive endoderm formation under these conditions closely parallels that following specification with elevated Activin A and low fetal calf serum (FCS)/knockout serum replacement (KSR). Reduced insulin/insulin-like growth factor (IGF) signaling was found to be critical for cell fate commitment into DE. Levels of insulin/IGF present in FCS/KSR, normally used to promote self-renewal of hESCs, antagonized differentiation. In summary, we show that generation of hESC-DE requires two conditions: signaling by Activin/Nodal family members and release from inhibitory signals generated by PI3K through insulin/IGF. These findings have important implications for our understanding of hESC self-renewal and early cell fate decisions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17204604     DOI: 10.1634/stemcells.2006-0219

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  179 in total

1.  The human embryonic stem cell proteome revealed by multidimensional fractionation followed by tandem mass spectrometry.

Authors:  Peng Zhao; Thomas C Schulz; Eric S Sherrer; D Brent Weatherly; Allan J Robins; Lance Wells
Journal:  Proteomics       Date:  2014-12-17       Impact factor: 3.984

2.  Generation of functional hepatic cells from pluripotent stem cells.

Authors:  Songyan Han; Alice Bourdon; Wissam Hamou; Noelle Dziedzic; Orit Goldman; Valerie Gouon-Evans
Journal:  J Stem Cell Res Ther       Date:  2012-08-15

Review 3.  Extrinsic regulation of pluripotent stem cells.

Authors:  Martin F Pera; Patrick P L Tam
Journal:  Nature       Date:  2010-06-10       Impact factor: 49.962

4.  Phosphatase and tensin homolog regulates the pluripotent state and lineage fate choice in human embryonic stem cells.

Authors:  Jackelyn A Alva; Grace E Lee; Erika E Escobar; April D Pyle
Journal:  Stem Cells       Date:  2011-12       Impact factor: 6.277

5.  Directing human embryonic stem cell differentiation by non-viral delivery of siRNA in 3D culture.

Authors:  Janet Zoldan; Abigail K R Lytton-Jean; Emmanouil D Karagiannis; Kaila Deiorio-Haggar; Leon M Bellan; Robert Langer; Daniel G Anderson
Journal:  Biomaterials       Date:  2011-08-11       Impact factor: 12.479

6.  Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling.

Authors:  Xiaojun Lian; Cheston Hsiao; Gisela Wilson; Kexian Zhu; Laurie B Hazeltine; Samira M Azarin; Kunil K Raval; Jianhua Zhang; Timothy J Kamp; Sean P Palecek
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

7.  Self-renewal of human embryonic stem cells requires insulin-like growth factor-1 receptor and ERBB2 receptor signaling.

Authors:  Linlin Wang; Thomas C Schulz; Eric S Sherrer; Derek S Dauphin; Soojung Shin; Angelique M Nelson; Carol B Ware; Mei Zhan; Chao-Zhong Song; Xiaoji Chen; Sandii N Brimble; Amanda McLean; Maria J Galeano; Elizabeth W Uhl; Kevin A D'Amour; Jonathan D Chesnut; Mahendra S Rao; C Anthony Blau; Allan J Robins
Journal:  Blood       Date:  2007-08-29       Impact factor: 22.113

Review 8.  Signaling networks in human pluripotent stem cells.

Authors:  Stephen Dalton
Journal:  Curr Opin Cell Biol       Date:  2012-10-22       Impact factor: 8.382

Review 9.  Cell Therapy for Type 1 Diabetes: Current and Future Strategies.

Authors:  Yasaman Aghazadeh; Maria Cristina Nostro
Journal:  Curr Diab Rep       Date:  2017-06       Impact factor: 4.810

10.  Stem cell therapy to treat diabetes mellitus.

Authors:  Chee Gee Liew; Peter W Andrews
Journal:  Rev Diabet Stud       Date:  2009-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.